Characterization of the overall survival benefit in ENCORE 301, a randomized, placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer

Category Primary study
JournalJournal of Clinical Oncology
Year 2012
This article has no abstract
Epistemonikos ID: 346336afcb11e455303d3d9a7d31e36ab0c414fd
First added on: Feb 05, 2025